Showing 2301-2310 of 7391 results for "".
New Topical Options for Psoriasis
https://practicaldermatology.com/topics/psoriasis/new-topical-options-for-psoriasis/19979/Leon Kircik, MD shares his excitement about new molecules for psoriasis. He discusses the available data for tapinarof, a first-in-class small-molecule topical therapeutic aryl hydrocarbon receptor (AhR)–modulating agent, and roflumilast cream, a once-daily topical formulation of roflumilast, a highPediatric Derm: Sunscreen and Insect Repellent Safety
https://practicaldermatology.com/conferences/aad-summer-2021/pediatric-derm-sunscreen-and-insect-repellent-safety/19973/Parents of pediatric dermatology patients often have lots of questions when it comes to sunscreen safety, especially in light of recent headlines about recalls and absorption concerns. Mercedes Gonzalez, MD offers tips for answering these burning questions, including knowing how to discuss availablePrescribing Biologics: Don't Be Afraid
https://practicaldermatology.com/conferences/aad-summer-2021/prescribing-biologics-dont-be-afraid/19969/Dermatologists have access to a growing armamentarium of safe and effective systemic therapies, but many physicians and patients are still hesitant to use them. Neal Bhatia, MD discusses the importance of prescribing biologics to patients with moderate to severe psoriasis to offer a safe and efficacLimited Liability Companies and Family Limited Partnerships, Part 2
https://practicaldermatology.com/topics/practice-management/limited-liability-companies-and-family-limited-partnerships-part-2/23529/How to maximize the protections of LLCs and FLPs.Scientifically Speaking: Diagnosing and Treating Hair Loss, Part 1
https://practicaldermatology.com/series/scientifically-speaking/scientifically-speaking-diagnosing-and-treating-hair-loss-part-1/19954/Hair loss is distressing for many patients. The first step in management is to identify the cause of hair loss, modify contributing factors, and develop an effective treatment plan. Host Joel L. Cohen, MD discusses the challenges of managing hair loss with Marc Avram, MD, Cheryl Burgess, MD, and ReeDermWireTV: GlobalSkin, ILDS Collab; New approach with Tafinlar; Equity in Telehealth; Dupixent pen
https://practicaldermatology.com/topics/practice-management/dermwiretv-globalskin-ilds-collab-new-approach-with-tafinlar-equity-in-telehealth-dupixent-pen/19952/A data analysis presented at the 2021 American Society of Clinical Oncology Annual Meeting shows that a new approach to managing fevers associated with dabrafenib increases treatment tolerability and avoids discontinuation of therapy. Global Skin (International Alliance of Dermatology Patient OrganiPower of the Group: Quality of Care in AD
https://practicaldermatology.com/topics/atopic-dermatitis/power-of-the-group-quality-of-care-in-ad/19880/When researchers undertook a survey of eczema centers worldwide, they uncovered common barriers to care and identified potential solutions. Eric Simpson, MD, MCR provides on overview of the Quality of Care in Atopic Dermatitis initiative, with an emphasis on the value of the group-based analysis ofFour Ways to Leverage Today’s Ultra-Low Interest Rates in Your Wealth Planning
https://practicaldermatology.com/topics/practice-management/four-ways-to-leverage-todays-ultra-low-interest-rates-in-your-wealth-planning/23401/Four tactics that may be beneficial for your financial health.COVID-19 Impact: Decisions, decisions: Treating Psoriasis
https://practicaldermatology.com/topics/psoriasis/covid-19-impact-decisions-decisions-treating-psoriasis/19770/Physicians need to carefully weigh the risks and benefits of treating psoriasis patients with biologics or immunosuppressant agents during the COVID-19 pandemic, says Jashin J. Wu, MD. Many factors affect this decision including the severity of the psoriasis as well as any underlying medical conditiToxin Time: What’s New and Exciting with Neuromodulators
https://practicaldermatology.com/topics/aesthetics-cosmeceuticals/toxin-time-whats-new-and-exciting-with-neuromodulators/19768/Joel Cohen, MD takes a deep dive into the most recent data on neuromodulators including post-hoc analyses on the potential durability of response. Dr. Cohen also shares updates on Revance’s DAXI, Botox Cosmetic and liquid toxins under development by Galderma and Allergan.